Verastem, Inc. (LON:0LOV)
London
· Delayed Price · Currency is GBP · Price in USD 5.68
+0.02 (0.30%)
At close: Feb 21, 2025
Verastem Revenue
Verastem had revenue of $10.00M USD in the twelve months ending September 30, 2024.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$136.99K
Employees
73
Market Cap
206.34M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| Hikma Pharmaceuticals | 2.39B |
| ConvaTec Group | 1.74B |
| HUTCHMED (China) | 483.31M |
| Genus | 668.80M |
Verastem News
- 25 days ago - Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Business Wire
- 4 weeks ago - Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 5 weeks ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 5 weeks ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 5 weeks ago - Verastem Oncology announces debt refinancing with Oberland Capital - Seeking Alpha
- 5 weeks ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire
- 6 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Verastem: Planning The PDUFA Run-Up - Seeking Alpha